TRISCEND II Trial: EVOQUE Transcatheter Tricuspid Valve Replacement (TTVR) Severe tricuspid regurgitation (TR) has historically been challenging to treat, with medical therapy offering limited relief. The TRISCEND II trial (2024) marks a significant milestone by assessing the safety and efficacy … Read More
Cardiovascular Disease
Landmark Clinical Trials of Aldosterone Antagonists
landmark clinical trials focusing on aldosterone antagonists (mineralocorticoid receptor antagonists) like spironolactone and eplerenone, which are commonly used in heart failure and other conditions: 1. RALES (1999) • Title: Randomized Aldactone Evaluation Study • Focus: Heart failure with reduced ejection … Read More
ACE-PROTAVI Trial: Protamine Administration for Bleeding in TAVR
The Impact of Routine Protamine Administration in Transcatheter Aortic Valve Implantation (TAVI): Insights from the ACE-PROTAVI Trial As advancements in heart valve interventions continue, minimizing post-procedural complications remains a top priority for healthcare professionals. One area of growing interest is … Read More
GLAGOV Trial: Evolocumab on CAD Progression
GLAGOV Trial: Effect of Evolocumab on Coronary Disease Progression in Statin-Treated Patients The GLAGOV trial is a double-blind, placebo-controlled, randomized study designed to assess the impact of PCSK9 inhibition with evolocumab on the progression of coronary atherosclerosis in patients already … Read More
VERONICA-Nigeria Trial: Triple-Pill for Hypertension
The VERONICA-Nigeria trial, published in JAMA in 2024, evaluated the efficacy and safety of a low-dose triple-pill protocol (telmisartan, amlodipine, and indapamide) versus a standard-care protocol for managing hypertension in Black African adults. This parallel-group, open-label, randomized controlled trial involved … Read More
EPIC-CAD Trial: Edoxaban in CAD and AF
The EPIC-CAD trial, recently published in The New England Journal of Medicine, evaluated the efficacy and safety of edoxaban monotherapy compared to dual antithrombotic therapy in patients with stable coronary artery disease (CAD) and high-risk atrial fibrillation (AF). This open-label, … Read More
MATTERHORN Trial Summary: Mitral Valve Repair vs. Surgery in Secondary MR
The MATTERHORN trial, published in The New England Journal of Medicine, investigates the efficacy of transcatheter repair (M-TEER) versus surgical mitral-valve repair for secondary mitral regurgitation (MR) in patients with heart failure. This randomized controlled trial included 208 patients, equally … Read More
OPT-BIRISK Trial: Clopidogrel Monotherapy in High Risk ACS
Trial Title: OPT-BIRISKStudy Type: Multicenter, double-blind, randomized trial Objective: To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in … Read More
SEQUOIA-HCM Trial: Aficamten in HCM
SEQUOIA-HCMAficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcome: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the SEQUOIA-HCM trial, comparing the outcomes of aficamten versus placebo in patients with … Read More
STOPDAPT-3 Trial: Prasugrel Monotherapy after PCI
STOPDAPT-3 TrialShort and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-3 Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcomes: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the STOPDAPT-3 trial, comparing the outcomes … Read More